Cinda Bio and Lilly Pharmaceuticals develop an innovative gastric acid regulator (OXM3)

Recently, Cinda Bio announced a strategic partnership with LillyPharmaceutical(http://to jointly promote the development and commercialization of an innovative gastric acid regulatory compound (OXM3) in ChinaAbout OXM3
OXM3 is a potentially optimal mid-species glucagon peptide-1 (GLP-1) and glucagon receptor double agonist in the middle stage of clinical developmentOXM3 is a natural peptide analogue derived from the transcription of the preglucecin gene in the intestinesSimilar to natural peptides, OXM3 binds and activates glucagon-like peptide-1 receptors (GLP-1R) and glucagon receptors (GCGR)OXM3 is a long-acting molecule that is injected once a weekIn theof early clinicaltrial sylactant(http:// OXM3 gastric acid-regulating molecules have demonstrated their role in effectively controlling blood sugar and reducing subjects' weight, demonstrating their potential efficacy in the treatment of diabetes, obesity and non-alcoholic fatty hepatitis (NASH)About Cinda Bio
Cinda Biopharma (Hong Kong Stock Exchange: 01801), is a biopharmaceutical company dedicated to the development, production and sale of new drug (http:// for the treatment of major
diseases such as tumors and autoimmune diseases, (http:// 　　Cinda Bio has formed a team of high-end biopharmaceutical development and industrialization talents with international advanced level, including many experts, and has reached strategic partnerships with international pharmaceutical companies such as Lilly Pharmaceuticals, Adimab, Incyte and Hanmi in South Korea 　　Cinda Bio hopes to work with you to improve the development level of China's biopharmaceutical industry to meet the people's drug availability and people's pursuit of life
health (http:// the pursuit of good wishes